Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

271.73USD
23 May 2018
Change (% chg)

$0.93 (+0.34%)
Prev Close
$270.80
Open
$268.16
Day's High
$272.73
Day's Low
$267.58
Volume
601,854
Avg. Vol
854,435
52-wk High
$273.00
52-wk Low
$167.98

Chart for

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $29,871.53
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

  ILMN.O Industry Sector
P/E (TTM): 40.23 148.43 32.75
EPS (TTM): 5.07 -- --
ROI: 18.76 9.37 14.38
ROE: 31.34 14.69 16.07

BRIEF-Illumina Acquires Edico Genome To Accelerate Genomic Data Analysis

* ILLUMINA ACQUIRES EDICO GENOME TO ACCELERATE GENOMIC DATA ANALYSIS Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Caredx Inc Enters Into A License And Commercialization Agreement With Illumina

* CAREDX INC - ON MAY 4, 2018, CO ENTERED INTO A LICENSE AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA, INC - SEC FILING

May 08 2018

BRIEF-Illumina Inc GAAP Earnings Per Share $1.41

* ILLUMINA REPORTS FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL YEAR 2018

Apr 24 2018

BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies

* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES

Apr 13 2018

Loxo, Illumina to partner for diagnostic tool targeting cancer

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

Apr 10 2018

UPDATE 1-Loxo, Illumina to partner for diagnostic tool targeting cancer

April 10 Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

Apr 10 2018

Loxo and Illumina in partnership over diagnostic for cancer drug

Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

Apr 10 2018

Loxo and Illumina in partnership over diagnostic for cancer drug

April 10 Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

Apr 10 2018

BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics

* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS

Apr 10 2018

BRIEF-Illumina Says CEO Francis Desouza's FY 2017 Total Compensation Was $8.8 Mln VS $8.4 Mln In FY 2016

* ILLUMINA SAYS PRESIDENT AND CEO FRANCIS DESOUZA'S FY 2017 TOTAL COMPENSATION WAS $8.8 MLN VS $8.4 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2H17H6F] Further company coverage:

Apr 06 2018

Earnings vs. Estimates